Jagsonpal Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd is trading at 199.00 as of 29 April 2026, with a FY2026-2027 high of 302 and low of 155. The stock is currently in the middle of its 52-week range. Market cap stands at 1,337 Cr..

Q: Is Jagsonpal Pharmaceuticals Ltd financially healthy?

Key indicators: ROCE of 23.0 % indicates efficient capital utilization. Dividend yield is 1.26 %.

Q: Is Jagsonpal Pharmaceuticals Ltd profitable and how is the profit trend?

Jagsonpal Pharmaceuticals Ltd reported a net profit of 55 Cr in Mar 2025 on revenue of 269 Cr. Compared to 19 Cr in Mar 2022, the net profit shows an improving trend.

Fair Value

₹179.31Fairly Valued by 9.89%vs CMP ₹199.00

P/E (31.4) × ROE (18.6%) × BV (₹37.90) × DY (1.26%)

₹96.34Overvalued by 51.59%vs CMP ₹199.00

MoS: -106.6% (Negative)Confidence: 66/100 (Moderate)Models: 1 Fair, 9 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹208.62	21%	Fair (+4.8%)
Graham Number	Earnings	₹72.36	15%	Over (-63.6%)
Earnings Power	Earnings	₹37.05	10%	Over (-81.4%)
DCF	Cash Flow	₹129.03	10%	Over (-35.2%)
Net Asset Value	Assets	₹41.08	7%	Over (-79.4%)
EV/EBITDA	Enterprise	₹69.06	8%	Over (-65.3%)
Dividend Discount	Dividends	₹55.00	8%	Over (-72.4%)
Earnings Yield	Earnings	₹61.40	7%	Over (-69.1%)
ROCE Capital	Returns	₹65.31	8%	Over (-67.2%)
Revenue Multiple	Revenue	₹40.04	5%	Over (-79.9%)
Consensus (10 models)		₹96.34	100%	Overvalued

Key Drivers: Wide model spread (₹37–₹209) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 16.3%

*Investments are subject to market risks

Analyst Summary

Jagsonpal Pharmaceuticals Ltd operates in the Pharmaceuticals segment, current market price is ₹199.00, market cap is 1,337 Cr.. At a glance, stock P/E is 31.4, ROE is 18.6 %, ROCE is 23.0 %, book value is 37.9, dividend yield is 1.26 %. The latest intrinsic value estimate is ₹96.34, around 51.6% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹269 Cr versus the prior period change of 28.7%, while latest net profit is about ₹55 Cr with a prior-period change of 150.0%. The 52-week range shown on this page is 302/155, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisJagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN)…

This summary is generated from the stock page data available for Jagsonpal Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Jagsonpal Pharmaceuticals Ltd scores 71/100 (Strong)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health92/100 · Strong

ROCE 23.0% ExcellentROE 18.6% ExcellentD/E 0.05 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent

Smart Money60/100 · Moderate

FII holding up 0.02% (6mo) Slight increasePromoter holding at 67.4% Stable

Earnings Quality60/100 · Moderate

OPM stable around 15% SteadyWorking capital: 9 days (improving) Efficient

Quarterly Momentum50/100 · Moderate

Revenue (4Q): +11% YoY GrowingProfit (4Q): -19% YoY Declining

Industry Rank85/100 · Strong

P/E 31.4 vs industry 59.5 Cheaper than peersROCE 23.0% vs industry 16.4% Above peersROE 18.6% vs industry 15.2% Above peers3Y sales CAGR: 7% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 25, 2026, 10:52 pm

Market Cap	1,337 Cr.
Current Price	199
Intrinsic Value	₹96.34
High / Low	302/155
Stock P/E	31.4
Book Value	37.9
Dividend Yield	1.26 %
ROCE	23.0 %
ROE	18.6 %
Face Value	2.00
PEG Ratio	1.92

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Jagsonpal Pharmaceuticals Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Jagsonpal Pharmaceuticals Ltd	1,337 Cr.	199	302/155	31.4	37.9	1.26 %	23.0 %	18.6 %	2.00
Beta Drugs Ltd	1,354 Cr.	1,336	2,000/990	31.4	219	0.00 %	27.0 %	25.9 %	10.0
TTK Healthcare Ltd	1,301 Cr.	920	1,402/735	18.7	768	1.09 %	9.26 %	6.89 %	10.0
Hester Biosciences Ltd	1,269 Cr.	1,492	2,350/1,239	31.0	397	0.47 %	9.71 %	9.18 %	10.0
Venus Remedies Ltd	1,269 Cr.	950	1,119/294	16.6	445	0.00 %	11.1 %	7.16 %	10.0
Industry Average	19,737.15 Cr	1,103.08		59.48	201.13	0.36%	16.35%	15.16%	6.10

All Competitor Stocks of Jagsonpal Pharmaceuticals Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	60	55	60	58	47	43	61	75	74	59	76	74	73
Expenses	52	50	52	49	44	41	51	58	58	50	61	58	57
Operating Profit	9	5	9	8	3	3	10	16	16	9	14	16	16
OPM %	14%	10%	14%	14%	7%	6%	17%	22%	21%	15%	19%	22%	22%
Other Income	2	3	2	2	3	2	-2	2	26	3	3	3	1
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	1	2	2	2	2	2	2
Profit before tax	10	7	10	10	5	5	7	15	39	9	14	17	15
Tax %	21%	24%	26%	25%	25%	22%	25%	25%	17%	24%	25%	25%	25%
Net Profit	8	6	7	7	4	4	5	11	32	7	11	13	11
EPS in Rs	1.19	0.85	1.14	1.14	0.60	0.54	0.81	1.73	4.82	0.99	1.62	1.89	1.64

Last Updated: February 5, 2026, 11:09 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 3:16 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	144	138	143	144	127	167	159	188	218	237	209	269	282
Expenses	133	129	132	138	138	157	150	169	192	203	186	218	226
Operating Profit	11	9	12	6	-11	9	9	19	26	34	23	51	56
OPM %	7%	6%	8%	4%	-9%	6%	5%	10%	12%	14%	11%	19%	20%
Other Income	0	0	1	13	0	1	3	4	3	2	9	28	9
Interest	5	4	5	3	1	1	1	1	0	0	1	1	1
Depreciation	3	3	3	2	0	1	1	1	2	1	2	8	9
Profit before tax	3	2	4	14	-12	9	9	22	27	35	30	70	54
Tax %	16%	30%	20%	18%	-1%	20%	16%	22%	29%	23%	25%	21%
Net Profit	2	1	3	12	-12	7	8	17	19	27	22	55	41
EPS in Rs	0.32	0.18	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40	8.34	6.14
Dividend Payout %	62%	22%	8%	2%	-2%	9%	17%	15%	56%	49%	59%	30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-50.00%	200.00%	300.00%	-200.00%	158.33%	14.29%	112.50%	11.76%	42.11%	-18.52%	150.00%
Change in YoY Net Profit Growth (%)	0.00%	250.00%	100.00%	-500.00%	358.33%	-144.05%	98.21%	-100.74%	30.34%	-60.62%	168.52%

Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	11%
3 Years:	7%
TTM:	35%

Compounded Profit Growth
10 Years:	42%
5 Years:	38%
3 Years:	29%
TTM:	87%

Stock Price CAGR
10 Years:	36%
5 Years:	75%
3 Years:	16%
1 Year:	45%

Return on Equity
10 Years:	10%
5 Years:	16%
3 Years:	17%
Last Year:	19%

Last Updated: September 5, 2025, 8:00 am

Balance Sheet

Last Updated: April 29, 2026, 3:30 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	82	85	97	85	91	98	109	120	146	174	227	263
Borrowings	39	38	8	8	4	5	7	0	6	9	9	8
Other Liabilities	19	22	25	23	28	31	35	31	30	21	29	32
Total Liabilities	154	159	143	130	136	147	164	164	195	217	278	317
Fixed Assets	52	52	22	21	22	22	26	23	24	9	94	85
CWIP	0	0	0	3	4	4	0	0	0	0	0	0
Investments	0	0	0	0	0	11	15	51	1	0	0	0
Other Assets	102	108	121	105	110	109	123	91	170	208	184	231
Total Assets	154	159	143	130	136	147	164	164	195	217	278	317

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	4	9	-3	-2	31	11	28	7	47	35	55	47
Cash from Investing Activity +	-0	-2	41	-3	-1	-11	-2	-26	-58	-25	-45	-36
Cash from Financing Activity +	-1	-6	-34	-1	-6	-1	-7	-18	-0	-9	-12	-12
Net Cash Flow	2	1	5	-6	24	-0	19	-36	-11	2	-2	-1
Free Cash Flow	4	6	40	-5	30	12	28	6	48	35	91	47
CFO/OP	53%	83%	-6%	14%	311%	150%	164%	54%	158%	189%	124%	101%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	11.00	-30.00	-26.00	-2.00	-19.00	5.00	4.00	12.00	26.00	28.00	14.00	42.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	115	119	106	100	73	45	49	25	26	32	19	18
Inventory Days	173	176	246	295	307	164	191	134	122	82	68	58
Days Payable	29	42	60	56	54	59	76	82	76	66	35	37
Cash Conversion Cycle	259	252	292	339	325	150	164	77	72	48	53	39
Working Capital Days	64	68	72	154	149	67	55	32	59	34	52	9
ROCE %	6%	5%	7%	3%	-10%	9%	9%	18%	20%	25%	17%	23%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	68.72%	68.72%	68.72%	68.48%	68.09%	68.04%	67.98%	67.82%	67.77%	67.65%	67.54%	67.39%
FIIs	0.10%	0.37%	0.38%	0.53%	0.73%	1.10%	2.30%	2.10%	2.10%	2.17%	2.12%	2.12%
DIIs	0.82%	0.82%	0.82%	0.82%	0.84%	0.84%	0.11%	0.00%	0.00%	0.05%	0.08%	0.15%
Public	30.34%	30.07%	30.07%	30.16%	30.33%	30.01%	29.63%	30.10%	30.11%	30.12%	30.25%	30.34%
No. of Shareholders	14,084	13,782	16,041	15,785	16,282	15,748	15,633	18,471	21,085	22,899	24,653	24,895

Shareholding Pattern Chart

No. of Shareholders

Jagsonpal Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	83	0.04	0	83	2025-04-22 17:25:30	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	2.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	8.26	8.49	10.20	7.48	6.51
Diluted EPS (Rs.)	8.22	8.46	10.20	7.48	6.51
Cash EPS (Rs.)	9.56	9.13	10.66	8.06	6.71
Book Value[Excl.RevalReserv]/Share (Rs.)	36.08	70.88	60.65	46.96	43.55
Book Value[Incl.RevalReserv]/Share (Rs.)	36.08	70.88	60.65	49.95	46.54
Dividend / Share (Rs.)	2.50	5.00	5.00	4.00	1.00
Revenue From Operations / Share (Rs.)	40.47	78.94	90.36	86.30	71.74
PBDIT / Share (Rs.)	8.92	12.23	15.22	11.12	8.96
PBIT / Share (Rs.)	7.70	11.61	14.76	10.54	8.76
PBT / Share (Rs.)	10.52	11.30	13.29	10.43	8.35
Net Profit / Share (Rs.)	8.34	8.50	10.20	7.48	6.51
PBDIT Margin (%)	22.05	15.49	16.84	12.88	12.48
PBIT Margin (%)	19.02	14.70	16.34	12.20	12.21
PBT Margin (%)	25.99	14.31	14.70	12.08	11.63
Net Profit Margin (%)	20.60	10.76	11.28	8.66	9.07
Return on Networth / Equity (%)	23.11	11.98	16.81	15.92	14.95
Return on Capital Employeed (%)	20.26	15.50	23.10	20.55	18.54
Return On Assets (%)	19.89	10.34	13.70	11.62	10.38
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.05
Asset Turnover Ratio (%)	1.08	1.01	1.30	1.36	1.21
Current Ratio (X)	6.22	10.42	5.97	3.24	2.98
Quick Ratio (X)	5.64	9.63	5.22	2.37	2.25
Inventory Turnover Ratio (X)	17.80	1.24	1.24	1.36	1.31
Dividend Payout Ratio (NP) (%)	23.89	58.31	0.00	53.50	15.35
Dividend Payout Ratio (CP) (%)	20.83	54.29	0.00	49.63	14.91
Earning Retention Ratio (%)	76.11	41.69	0.00	46.50	84.65
Cash Earning Retention Ratio (%)	79.17	45.71	0.00	50.37	85.09
Interest Coverage Ratio (X)	61.86	39.74	96.57	102.18	21.61
Interest Coverage Ratio (Post Tax) (X)	38.24	28.60	74.08	69.70	16.71
Enterprise Value (Cr.)	1305.18	591.93	644.85	795.42	154.96
EV / Net Operating Revenue (X)	4.86	2.84	2.72	3.52	0.82
EV / EBITDA (X)	22.02	18.30	16.17	27.31	6.60
MarketCap / Net Operating Revenue (X)	5.34	3.54	3.21	3.63	1.11
Retention Ratios (%)	76.10	41.68	0.00	46.49	84.64
Price / BV (X)	5.99	3.95	4.78	6.68	1.83
Price / Net Operating Revenue (X)	5.34	3.54	3.21	3.63	1.11
EarningsYield	0.03	0.03	0.03	0.02	0.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 287.23 Cr. and Equity Capital is Rs. 13.39 Cr. for the Year ended 31/03/2026.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Innov8 3rd Floor, New Delhi Delhi 110020	Contact not found

Management
Name	Position Held
Mr. Rajpal Singh Kochhar	Chairman Emeritus
Mr. Harsha Raghavan	Chairman & Non-Exe.Director
Mr. Manish Gupta	Managing Director
Mr. Prithipal Singh Kochhar	Non Executive Director
Mr. Debasis Bikash Nandy	Independent Director
Ms. Radhika Madhukar Dudhat	Independent Director
Ms. Pallavi Dinodia Gupta	Independent Director

FAQ

What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd and is it undervalued?

As of 29 April 2026, Jagsonpal Pharmaceuticals Ltd's intrinsic value is ₹96.34, which is 51.59% lower than the current market price of ₹199.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (18.6 %), book value (₹37.9), dividend yield (1.26 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd is trading at ₹199.00 as of 29 April 2026, with a FY2026-2027 high of ₹302 and low of ₹155. The stock is currently in the middle of its 52-week range. Market cap stands at ₹1,337 Cr..

How does Jagsonpal Pharmaceuticals Ltd's P/E ratio compare to its industry?

Jagsonpal Pharmaceuticals Ltd has a P/E ratio of 31.4, which is below the industry average of 59.48. This is broadly in line with or below the industry average.

Is Jagsonpal Pharmaceuticals Ltd financially healthy?

Key indicators for Jagsonpal Pharmaceuticals Ltd: ROCE of 23.0 % indicates efficient capital utilization; ROE of 18.6 % shows strong shareholder returns. Dividend yield is 1.26 %.

Is Jagsonpal Pharmaceuticals Ltd profitable and how is the profit trend?

Jagsonpal Pharmaceuticals Ltd reported a net profit of ₹55 Cr in Mar 2025 on revenue of ₹269 Cr. Compared to ₹19 Cr in Mar 2022, the net profit shows an improving trend.

Does Jagsonpal Pharmaceuticals Ltd pay dividends?

Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.26 % at the current price of ₹199.00. The company pays dividends, though the yield is modest.